These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752 [TBL] [Abstract][Full Text] [Related]
3. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Kircheis G; Wettstein M; Dahl Sv; Häussinger D Metab Brain Dis; 2002 Dec; 17(4):453-62. PubMed ID: 12602521 [TBL] [Abstract][Full Text] [Related]
5. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582 [TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Mittal VV; Sharma BC; Sharma P; Sarin SK Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910 [TBL] [Abstract][Full Text] [Related]
8. Current state of knowledge of hepatic encephalopathy (Part V): clinical efficacy of L-ornithine-L-aspartate in the management of HE. Kircheis G Metab Brain Dis; 2016 Dec; 31(6):1365-1367. PubMed ID: 27838865 [TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040 [TBL] [Abstract][Full Text] [Related]
10. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study. Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596 [TBL] [Abstract][Full Text] [Related]
12. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. Sidhu SS; Sharma BC; Goyal O; Kishore H; Kaur N Hepatology; 2018 Feb; 67(2):700-710. PubMed ID: 28749571 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Blanco Vela CI; Poo Ramírez JL Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883 [TBL] [Abstract][Full Text] [Related]
14. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]. Chen MF; Li RC; Chen CH; Gao XC Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319 [TBL] [Abstract][Full Text] [Related]
15. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)]. Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303 [TBL] [Abstract][Full Text] [Related]
16. Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Ong JP; Oehler G; Krüger-Jansen C; Lambert-Baumann J; Younossi ZM Clin Drug Investig; 2011; 31(4):213-20. PubMed ID: 21208014 [TBL] [Abstract][Full Text] [Related]
17. [Prevention and treatment of hepatic encephalopathy]. Sivolap YP Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503 [TBL] [Abstract][Full Text] [Related]
18. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Rees CJ; Oppong K; Al Mardini H; Hudson M; Record CO Gut; 2000 Oct; 47(4):571-4. PubMed ID: 10986219 [TBL] [Abstract][Full Text] [Related]
19. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy. Ndraha S; Simadibrata M Acta Med Indones; 2010 Jul; 42(3):158-61. PubMed ID: 20724770 [TBL] [Abstract][Full Text] [Related]
20. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]